Breast Cancer

Clinical trial in Spain will test efficacy of capecitabine

Published in Women's Health Weekly, May 20th, 2004

Two institutions in Spain are conducting a clinical trial of the efficacy of capecitabine therapy in women who have had breast cancer operations and who have been diagnosed with ganglions in the axilas.

Capecitabine is a product of Roche Laboratories Inc., which markets the drug as Xeloda for metastatic colorectal cancer and certain cases of metastatic breast cancer.

The research is being conducted at the Gipuzkoa Cancer Institute and the Donostia-San Sebastian General Hospital, as well as some 60 other Spanish centers, with a total of 1,500 women participating. The length of the treatment is 28 weeks and the results will be known within 4...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2004-05-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry